These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34551375)

  • 1. Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia.
    Willemse EAJ; Sieben A; Somers C; Vermeiren Y; De Roeck N; Timmers M; Van Broeckhoven C; De Vil B; Cras P; De Deyn PP; Martin JJ; Teunissen CE; Engelborghs S; Bjerke M
    Neurobiol Aging; 2021 Dec; 108():99-109. PubMed ID: 34551375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
    Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias.
    Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Polischi B; Capellari S; Parchi P
    Alzheimers Res Ther; 2023 Sep; 15(1):150. PubMed ID: 37684653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
    Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE
    Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer's Disease.
    Hermann P; Haller P; Goebel S; Bunck T; Schmidt C; Wiltfang J; Zerr I
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration.
    Höglund K; Schussler N; Kvartsberg H; Smailovic U; Brinkmalm G; Liman V; Becker B; Zetterberg H; Cedazo-Minguez A; Janelidze S; Lefevre IA; Eyquem S; Hansson O; Blennow K
    Neurobiol Dis; 2020 Feb; 134():104645. PubMed ID: 31669672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.
    Portelius E; Olsson B; Höglund K; Cullen NC; Kvartsberg H; Andreasson U; Zetterberg H; Sandelius Å; Shaw LM; Lee VMY; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk DA; McCluskey L; Elman L; McBride J; Toledo JB; Trojanowski JQ; Blennow K
    Acta Neuropathol; 2018 Sep; 136(3):363-376. PubMed ID: 29700597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.
    Antonell A; Tort-Merino A; Ríos J; Balasa M; Borrego-Écija S; Auge JM; Muñoz-García C; Bosch B; Falgàs N; Rami L; Ramos-Campoy O; Blennow K; Zetterberg H; Molinuevo JL; Lladó A; Sánchez-Valle R
    Alzheimers Dement; 2020 Feb; 16(2):262-272. PubMed ID: 31668967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.
    Kvartsberg H; Lashley T; Murray CE; Brinkmalm G; Cullen NC; Höglund K; Zetterberg H; Blennow K; Portelius E
    Acta Neuropathol; 2019 Jan; 137(1):89-102. PubMed ID: 30244311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
    Kvartsberg H; Duits FH; Ingelsson M; Andreasen N; Öhrfelt A; Andersson K; Brinkmalm G; Lannfelt L; Minthon L; Hansson O; Andreasson U; Teunissen CE; Scheltens P; Van der Flier WM; Zetterberg H; Portelius E; Blennow K
    Alzheimers Dement; 2015 Oct; 11(10):1180-90. PubMed ID: 25533203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer's disease.
    Xue M; Sun FR; Ou YN; Shen XN; Li HQ; Huang YY; Dong Q; Tan L; Yu JT;
    Aging (Albany NY); 2020 May; 12(10):9365-9379. PubMed ID: 32421689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.
    Clarke MTM; Brinkmalm A; Foiani MS; Woollacott IOC; Heller C; Heslegrave A; Keshavan A; Fox NC; Schott JM; Warren JD; Blennow K; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2019 Dec; 11(1):105. PubMed ID: 31847891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of synaptic biomarkers in the spectrum of neurodegenerative diseases.
    Mazzucchi S; Palermo G; Campese N; Galgani A; Della Vecchia A; Vergallo A; Siciliano G; Ceravolo R; Hampel H; Baldacci F
    Expert Rev Proteomics; 2020; 17(7-8):543-559. PubMed ID: 33028119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurogranin as a Novel Biomarker in Alzheimer's Disease.
    Agnello L; Gambino CM; Lo Sasso B; Bivona G; Milano S; Ciaccio AM; Piccoli T; La Bella V; Ciaccio M
    Lab Med; 2021 Mar; 52(2):188-196. PubMed ID: 32926148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.
    Grangeon L; Paquet C; Bombois S; Quillard-Muraine M; Martinaud O; Bourre B; Lefaucheur R; Nicolas G; Dumurgier J; Gerardin E; Jan M; Laplanche JL; Peoc'h K; Hugon J; Pasquier F; Maltête D; Hannequin D; Wallon D;
    J Alzheimers Dis; 2016; 51(3):905-13. PubMed ID: 26890785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurogranin in Alzheimer's disease and ageing: A human post-mortem study.
    Saunders T; Gunn C; Blennow K; Kvartsberg H; Zetterberg H; Shenkin SD; Cox SR; Deary IJ; Smith C; King D; Spires-Jones T
    Neurobiol Dis; 2023 Feb; 177():105991. PubMed ID: 36623608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease.
    Dorey A; Tholance Y; Vighetto A; Perret-Liaudet A; Lachman I; Krolak-Salmon P; Wagner U; Struyfs H; De Deyn PP; El-Moualij B; Zorzi W; Meyronet D; Streichenberger N; Engelborghs S; Kovacs GG; Quadrio I
    JAMA Neurol; 2015 Mar; 72(3):267-75. PubMed ID: 25559883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.